Project

A 24 weeks activity program in patients with early breast cancer receiving aromatase inhibitor therapy. A multicenter randomized phase III trial.

Completed · 2019 until 2023

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2019
End Date
2023
Financing
SAKK
Labels
breast cancer
Brief description/objective